Jack Allen
Stock Analyst at Baird
(1.54)
# 3,439
Out of 5,172 analysts
43
Total ratings
41.18%
Success rate
-8.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $106 → $115 | $114.77 | +0.20% | 6 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $46.24 | -4.84% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $12.04 | +431.56% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.40 | +172.73% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.10 | +263.64% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $2.07 | +334.78% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $9.41 | +325.08% | 2 | Nov 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $12.84 | +40.19% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $8.52 | +2,012.68% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.34 | +2,239.18% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $29.91 | +180.84% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.45 | +244.83% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.34 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.85 | +134.07% | 1 | Oct 7, 2021 |
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $106 → $115
Current: $114.77
Upside: +0.20%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $46.24
Upside: -4.84%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $12.04
Upside: +431.56%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.40
Upside: +172.73%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.10
Upside: +263.64%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $2.07
Upside: +334.78%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $9.41
Upside: +325.08%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $12.84
Upside: +40.19%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $8.52
Upside: +2,012.68%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.34
Upside: +2,239.18%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $29.91
Upside: +180.84%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.45
Upside: +244.83%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.34
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.85
Upside: +134.07%